Calciphylaxis Treatment Market Report 2026

The calciphylaxis treatment market size has grown strongly in recent years. It will grow from $2.03 billion in 2025 to $2.2 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to improved understanding of calciphylaxis pathology, increased diagnosis among ESRD patients, availability of supportive pharmacological treatments, expansion of hospital-based treatment protocols, growing clinical research initiatives.

The calciphylaxis treatment market size is expected to see strong growth in the next few years. It will grow to $3.03 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing development of targeted drug therapies, rising adoption of combination treatment approaches, expansion of specialized calciphylaxis treatment centers, growing investment in rare disease therapeutics, increasing focus on improving patient survival outcomes. Major trends in the forecast period include increasing use of sodium thiosulfate therapy, rising adoption of hyperbaric oxygen treatment, growing focus on multidisciplinary disease management, expansion of advanced wound care interventions, enhanced emphasis on early therapeutic intervention.

The rising prevalence of kidney diseases is anticipated to drive the growth of the calciphylaxis treatment market in the coming years. Kidney diseases encompass a broad range of medical conditions and disorders that impair the function of the kidneys, which are essential organs responsible for filtering waste products and excess fluids from the blood to produce urine. These conditions interfere with calcium and phosphate metabolism, thereby increasing the risk of calciphylaxis and creating a need for advanced diagnostic approaches and effective treatment options to manage the disorder. For example, in June 2023, Kidney Research UK, a UK-based charitable organization, reported that approximately 7.19 million people in the UK were living with chronic kidney disease in 2023, accounting for over 10% of the total population, with projections indicating an increase to 7.61 million individuals by 2033. Consequently, the increasing burden of kidney diseases is expected to fuel the expansion of the calciphylaxis treatment market.

Leading companies in the calciphylaxis treatment market are focusing on the development of advanced diagnostic methods and health assessment kits and services, including the deployment of in-home chronic kidney disease diagnostic and preventive solutions, to improve early detection and patient-centered care outcomes. In-home chronic kidney disease diagnostic and preventive services deployment involves a structured approach to delivering kidney health evaluations, early identification of chronic kidney disease, and preventive healthcare measures directly in patients’ homes, with the goal of enhancing clinical outcomes, improving access to diagnostics, and easing the strain on conventional healthcare systems. For example, in August 2023, Signify Health, Inc., a US-based healthcare company, launched a comprehensive in-home kidney health evaluation as part of its diagnostic and preventive service offerings, designed to support the early detection, diagnosis, and management of chronic kidney-related conditions. These in-home assessments include urinalysis (uACR) and estimated glomerular filtration rate (eGFR) testing, which provide essential insights to guide treatment decisions such as further diagnostic testing, lifestyle modifications, medication management, or referral to a nephrology specialist. This service is particularly beneficial for conditions like calciphylaxis, a rare disease marked by calcium accumulation in small blood vessels and commonly associated with end-stage renal disease, as it enables earlier diagnosis and timely intervention.

In January 2024, Merck KGaA, a Germany-based science and technology company involved in calciphylaxis treatment, entered into a partnership with Inspirna Inc. Through this collaboration, Merck KGaA strengthened its colorectal cancer portfolio via a licensing agreement for ompenaclid (RGX-202). This first-in-class oral inhibitor targets the creatine transport channel SLC6A8 and is currently undergoing Phase II clinical development for advanced RAS-mutated colorectal cancer (mCRC). Inspirna Inc. is a US-based clinical-stage biopharmaceutical company.

Major companies operating in the calciphylaxis treatment market are Pfizer Inc., Merck And Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Sanofi SA, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Novo Nordisk, Viatris, Regeneron Pharmaceuticals Inc., Incyte Corporation, Vifor Pharma Group, Panion And BF Biotech Inc., Inozyme Pharma Inc., Sanifit Therapeutics S.A., Hope Pharmaceuticals, Menlo Therapeutics.

North America was the largest region in the calciphylaxis treatment market in 2025 Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calciphylaxis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the calciphylaxis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the calciphylaxis treatment market by increasing costs of imported pharmaceuticals, hyperbaric oxygen systems, diagnostic tools, and advanced wound care products. Hospitals and research centers in North America and Europe are most affected due to dependence on imported medical technologies, while Asia-Pacific faces higher costs in expanding treatment infrastructure. These tariffs are increasing therapy costs and slowing treatment accessibility. However, they are also driving domestic pharmaceutical manufacturing, regional production of medical devices, and increased focus on cost-effective treatment innovations.

The calciphylaxis treatment market research report is one of a series of new reports that provides calciphylaxis treatment market statistics, including calciphylaxis treatment industry global market size, regional shares, competitors with a calciphylaxis treatment market share, detailed calciphylaxis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the calciphylaxis treatment industry. This calciphylaxis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare and serious medical disorder marked by the deposition of calcium in small blood vessels and surrounding tissues, most commonly affecting individuals with kidney disease, particularly those with end-stage renal disease (ESRD). Its treatment focuses on pain control and nutritional support to help manage and relieve symptoms such as painful, non-healing skin ulcers, tissue necrosis, and severe complications like sepsis, which can be life-threatening.

The primary categories of calciphylaxis treatment include medication, hyperbaric oxygen therapy, and other supportive approaches. Medication involves the use of pharmaceutical agents to address symptoms and underlying factors of the condition, with drugs such as sodium thiosulfate, opioids, and non-opioid therapies used to manage pain, prevent or treat infections, and support overall care in calciphylaxis. Diagnosis is carried out using imaging techniques, blood tests, and deep skin biopsies, with these procedures performed by end users including hospitals, clinics, medical research centers, and academic institutions.

The calciphylaxis treatment market consists of revenues earned by entities by providing diagnostic services such as infrared thermography, electrolyte and mineral analysis, and measuring serum parathyroid hormone (PTH) levels to diagnose and assess the severity of calciphylaxis in patients. The market value includes the value of related goods sold by the service provider or included within the service offering. The calciphylaxis treatment market also includes sales of intensive wound care, clot-dissolving therapy, and vitamin K therapy, which are comprehensive treatment approaches for managing calciphylaxis. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.